Risk factors for hepatitis C virus (HCV) infection vary, and there were an estimated 1.75
million new cases worldwide in 2015. The World Health Organization aims for a 90 …

Hepatitis C virus (HCV) is a blood borne disease estimated to chronically infect 3% of the
worlds' population causing significant morbidity and mortality. Current medical therapy is …

A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme
variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize …

Porcine reproductive and respiratory syndrome virus (PRRSV) contains the major
glycoprotein, GP5, as well as three other minor glycoproteins, namely, GP2a, GP3, and GP4 …

The variability of the hepatitis C virus (HCV), which likely contributes to immune escape, is
most pronounced in hypervariable region 1 (HVR1) of viral envelope protein 2. This domain …

Hepatitis C virus (HCV) cell entry involves interaction between the viral envelope
glycoprotein E2 and the cell surface receptor CD81. Knowledge of conserved E2 …

Nearly all livers transplanted into hepatitis C virus (HCV)-positive patients become infected
with HCV, and 10 to 25% of reinfected livers develop cirrhosis within 5 years. Neutralizing …

Cellular binding and entry of hepatitis C virus (HCV) are the first steps of viral infection and
represent a major target for antiviral antibodies and novel therapeutic strategies. We have …

Hepatitis C virus (HCV) infects cells by the direct uptake of cell-free virus following virus
engagement with specific cell receptors such as CD81. Recent data have shown that HCV is …

Hepatitis C Virus (HCV) infection is a global public health problem affecting over 160 million
individuals worldwide. Its symptoms include chronic hepatitis, liver cirrhosis and …